SiPeng Technology Secures Nearly RMB 100 Million in Pre-A Funding to Accelerate Carbon-Negative Bio-Manufacturing Platform

VCBeat has learned that Shanghai Sipeng Technology Co., Ltd. (hereinafter referred to as “Sipeng Technology”) recently announced the completion of its Pre-A financing round, which raised nearly RMB 100 million. This round of investment was led bySDIC ChuangheLead Investor,Rugao Sci-Tech Innovation InvestmentCo-investment,Xiqiao CapitalServed as the exclusive financial advisor. The funds raised will be used to further strengthen the mass production and commercial promotion of biomanufacturing products.

Sipeng Technology is a representative enterprise in the commercialization of scientific and technological achievements from Shanghai Jiao Tong University.Leveraging the Shanghai Municipal Major Science and Technology Special Project and the CNSB (Carbon Negative Synthetic Biology) major project funded by the National Research Foundation of Singapore, Sipeng Technology will continue to optimize and iterate carbon sources, accelerating industrial breakthroughs in non-food negative-carbon manufacturing.

SiPeng Tech, established in 2022, is a biomanufacturing company specializing in materials synthetic biology. The founding team has over two decades of deep industry experience, with extensive R&D and production expertise in bio-based materials. They have achieved breakthroughs in multiple “chokepoint” technologies and developed core products for numerous industry-leading enterprises.Proven track record of successfully scaling up and commercializing multiple biomanufacturing products.

Figure: A corner of the State Key Laboratory of Microbial Metabolism, the company’s technology source hub

Over the two years since its establishment, the company has achieved rapid growth. In the field of upstream monomer biosynthesis for materials, leveraging the team’s years of accumulated expertise, the company possesses an extensive library of genetic elements and dozens of mature industrial chassis strains. These relevant strains are at the international leading level in terms of fermentation titer, conversion rate, and robustness. Based on this, the companyMultiple bio-based polyol products have completed mass production validation., it is widely used in fields such as polyesters, cosmetics, agriculture, and pharmaceuticals. It has established a deep strategic partnership with Angel Yeast Group, the world’s second-largest yeast enterprise, and completed the construction of a production line for the mass production of polyols at the thousand-ton scale.

In the field of downstream polymerization modification application development, the company has completed the formulation development of nearly 100 types of bio-based materials, established ISO-certified production lines, and partnered with numerous well-known brands domestically and internationally, gaining entry into their supplier systems.

Figure: The company's self-built ton-scale synthetic biology pilot validation platform

Figure: The company and Angel Yeast collaborate on a thousand-ton-scale mass production line for polyols.

Xu Ping, Founder and Chief Scientist of Sipeng Technologystated: “Negative-carbon intelligent manufacturing is an emerging interdisciplinary field and an inevitable trend in biomanufacturing. In the past, we have received strong support from various institutions, including Shanghai Jiao Tong University, the Shanghai Municipal Government, and the Singapore Government. We appreciate the recognition from both new and existing investors such as SDIC Chuanghe and Rugao Science and Technology Innovation Venture Capital. With your steadfast support, we are confident that our team will be the first globally to achieve industrial breakthroughs in non-grain-based negative-carbon manufacturing.”

Tao Fei, Founder and Chairman of SiPeng TechnologyHe stated, “The key differences between biomanufacturing and traditional manufacturing lie primarily in the transformation of raw materials and production methods. This shift ultimately enables a country or region to break free from the constraints of its own geographical resource endowments, thereby allowing for the unrestricted provision of high-quality products. Sifan Tech will continue to be market-demand driven, building long-term competitive advantages through strain iteration, carbon source substitution, and continuous optimization of production processes, while bringing more superior products to the market.”

SDIC Chuanghe Biopharmaceutical Teamstated: “Against the backdrop of China’s ‘dual carbon’ goals and sustainable development, bio-based materials boast promising long-term prospects and are expected to gradually replace petroleum-based materials, serving as a highlight of green, low-carbon economic growth. The Sifan team possesses profound technical expertise in strain development and construction, along with extensive experience in industrial commercialization. Leveraging its leading platforms for strain engineering and material modification, Sifan Technology has achieved rapid growth since its establishment, forming a diverse product portfolio with distinct technological advantages. SDIC Chuanghe will fully leverage its industrial ecosystem resources to support Sifan Technology’s continuous independent innovation, accompanying and assisting the company in contributing to China’s biomanufacturing industry and becoming a global leader in bio-based materials.”

Rugao Sci-Tech Innovation Investment“He stated, ‘The bio-based materials industry is gradually maturing. Sipeng Technology has fully leveraged the combined advantages of its team’s R&D capabilities and industrialization experience, resulting in products with distinctly differentiated features. The Sci-Tech Innovation Investment Group focuses on the field of synthetic biology and has engaged in deep cooperation with Sipeng Technology, providing comprehensive services to support the company’s steady development.’”

Li Xinyi, Head of the Synthetic Biology Sector at Xi Qiao Capitalstated, “It is a great honor to accompany Sifan Technology in its development. Biomaterials offer substantial growth opportunities and vast market potential, and we look forward to the future launch of more globally competitive products from the company.”